NO924309L - Sammensetninger og fremgangsmaater for modulering av rna-aktiviteter gjennom modifikasjon av 5' cap-strukturen til rna - Google Patents

Sammensetninger og fremgangsmaater for modulering av rna-aktiviteter gjennom modifikasjon av 5' cap-strukturen til rna

Info

Publication number
NO924309L
NO924309L NO92924309A NO924309A NO924309L NO 924309 L NO924309 L NO 924309L NO 92924309 A NO92924309 A NO 92924309A NO 924309 A NO924309 A NO 924309A NO 924309 L NO924309 L NO 924309L
Authority
NO
Norway
Prior art keywords
rna
cap structure
modification
procedures
compositions
Prior art date
Application number
NO92924309A
Other languages
English (en)
Norwegian (no)
Other versions
NO924309D0 (no
Inventor
Brenda F Baker
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of NO924309L publication Critical patent/NO924309L/no
Publication of NO924309D0 publication Critical patent/NO924309D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO924309A 1990-05-23 1992-11-09 Sammensetninger og fremgangsmaater for modulering av rna-aktiviteter gjennom modifikasjon av 5' cap-strukturen til rna NO924309D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52759990A 1990-05-23 1990-05-23
PCT/US1991/003606 WO1991017755A1 (en) 1990-05-23 1991-05-22 Compositions and methods for modulating rna activity through modification of the 5' cap structure of rna

Publications (2)

Publication Number Publication Date
NO924309L true NO924309L (no) 1992-11-09
NO924309D0 NO924309D0 (no) 1992-11-09

Family

ID=24102143

Family Applications (1)

Application Number Title Priority Date Filing Date
NO924309A NO924309D0 (no) 1990-05-23 1992-11-09 Sammensetninger og fremgangsmaater for modulering av rna-aktiviteter gjennom modifikasjon av 5' cap-strukturen til rna

Country Status (15)

Country Link
EP (1) EP0531447B1 (da)
JP (1) JPH06500075A (da)
KR (1) KR960004931B1 (da)
AT (1) ATE186464T1 (da)
AU (1) AU649458B2 (da)
BR (1) BR9106486A (da)
CA (1) CA2083377C (da)
DE (1) DE69131773T2 (da)
DK (1) DK0531447T3 (da)
ES (1) ES2139578T3 (da)
FI (1) FI925210A0 (da)
GR (1) GR3032457T3 (da)
HU (1) HUT63568A (da)
NO (1) NO924309D0 (da)
WO (1) WO1991017755A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789573A (en) * 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
EP0691853B1 (en) * 1993-04-01 2002-06-05 Isis Pharmaceuticals, Inc. ANTISENSE OLIGOS WHICH INTERFERE WITH mRNA CAP ACTIVITY AND INHIBIT TRANSLATION
IL114235A0 (en) * 1994-07-14 1995-10-31 Schering Ag Oligonucleotide conjugates and processes for noninvasive diagnosis utilizing the same
US6380169B1 (en) * 1994-08-31 2002-04-30 Isis Pharmaceuticals, Inc. Metal complex containing oligonucleoside cleavage compounds and therapies
US5962271A (en) * 1996-01-03 1999-10-05 Cloutech Laboratories, Inc. Methods and compositions for generating full-length cDNA having arbitrary nucleotide sequence at the 3'-end
AU2001239856A1 (en) * 2000-02-25 2001-09-03 Tao Biosciences, Llc Platform for the discovery of the bacterial genes involved in rna modification
CA2744987C (en) 2008-12-02 2018-01-16 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
AU2010270714B2 (en) 2009-07-06 2015-08-13 Wave Life Sciences Ltd. Novel nucleic acid prodrugs and methods use thereof
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
SG10201700554VA (en) 2011-07-19 2017-03-30 Wave Life Sciences Pte Ltd Methods for the synthesis of functionalized nucleic acids
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
BR112015000723A2 (pt) 2012-07-13 2017-06-27 Shin Nippon Biomedical Laboratories Ltd adjuvante de ácido nucléico quiral
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
MX2016009290A (es) 2014-01-16 2017-02-28 Wave Life Sciences Ltd Diseño quiral.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
EP0604409B1 (en) * 1990-01-11 2004-07-14 Isis Pharmaceuticals, Inc. Oligonucleotide analogs for detecting and modulating rna activity and gene expression

Also Published As

Publication number Publication date
DE69131773T2 (de) 2000-03-02
HUT63568A (en) 1993-09-28
EP0531447A1 (en) 1993-03-17
FI925210A (fi) 1992-11-17
BR9106486A (pt) 1993-05-25
DK0531447T3 (da) 2000-03-27
EP0531447A4 (en) 1993-08-11
CA2083377C (en) 2002-11-26
KR930700118A (ko) 1993-03-13
FI925210A0 (fi) 1992-11-17
JPH06500075A (ja) 1994-01-06
HU9203659D0 (en) 1993-04-28
AU649458B2 (en) 1994-05-26
GR3032457T3 (en) 2000-05-31
AU8080291A (en) 1991-12-10
CA2083377A1 (en) 1991-11-24
KR960004931B1 (ko) 1996-04-18
DE69131773D1 (de) 1999-12-16
NO924309D0 (no) 1992-11-09
ES2139578T3 (es) 2000-02-16
ATE186464T1 (de) 1999-11-15
EP0531447B1 (en) 1999-11-10
WO1991017755A1 (en) 1991-11-28

Similar Documents

Publication Publication Date Title
NO924309D0 (no) Sammensetninger og fremgangsmaater for modulering av rna-aktiviteter gjennom modifikasjon av 5' cap-strukturen til rna
DK288183A (da) Fremgangsmaade til fremstilling af et oligonucleotidt terapeutisk middel
PL334530A1 (en) Novel genes specific in respect to n-axecetyl-l-phosphotricin, used to code amino acids deacetylase, their isolation and application
GEP20022701B (en) Modulators of Body Weight, Corresponding Nucleic Acids and Proteins, and Diagnostic and Therapeutic Uses Thereof
DE69721006D1 (de) Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen
GB9402857D0 (en) Targeting gene therapy
DE60042137D1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
PT93393A (pt) Processo para a preparacao de vacinas e de agentes de diagnostico que contem regioes imunogenicas de proteina e7do virus do papiloma humano do tipo 16 ou anticorpos suscitados contra estas regioes
PT1053313E (pt) Oligonucleotidos ''antisense'' optimizados complementares de sequencias de dna metiltransferase
ATE267247T1 (de) Reagenz und verfahren zur inhibierung der n-ras expression
EP1123414A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF INTEGRIN ALPHA 4
DE69032080D1 (de) Verwendung von konservierten Oligonukleotid-Primern zur Amplifizierung von menschlichen Papillomavirus-DNS-Sequenzen
DE69333491D1 (en) Protease-resistente analoge des thrombomodulin
KR950700079A (ko) 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease)
DE68904462D1 (de) 4-chinolincarbonsaeure-derivate, brauchbar zur behandlung von haut- und muco-epithelial-gewebekrankheiten.
FI103577B1 (fi) Menetelmä, DNA ja mikro-organismi trombolyyttisen aineen valmistamiseksi
DE69333812D1 (de) Endo-Xyloglucan-Transferase
MY101874A (en) Vaccine
DE19681032D2 (de) Gentherapeutisches Nukleinsäurekonstrukt, seine Herstellung und Verwendung zur Behandlung von Herzerkrankungen
DE59410423D1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
ATE218372T1 (de) Antisense oligonnukleotide die mit der mrna cap aktivität interferieren und die translation inhibieren
UA10281C2 (uk) Спосіб отримання речовини для лікування захворювань підшлункової залози
AU2782989A (en) Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
EA199800941A1 (ru) Терапевтические средства, содержащие кислородные анион-радикалы и/или продукты их последующего превращения и расщепления, и их применение для лечения болезни паркинсона
AU6031598A (en) Enzymatic nucleic acid treatment of diseases or conditions related to levels of c-fos